Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to
determine the effect of ranolazine when given as monotherapy on glycemic control in subjects
with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise
alone and who are treatment naive to antihyperglycemic therapy or have not received
antihyperglycemic therapy in the 90 days (or thiazolidinediones [TZDs] for at least 24 weeks)
prior to screening, and to characterize the relationship between HbA1c reduction and other
glycemic parameters in subjects with T2DM.